{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:11:58Z","timestamp":1756339918356,"version":"3.44.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,27]]},"DOI":"10.7759\/cureus.91143","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T23:41:32Z","timestamp":1756338092000},"source":"Crossref","is-referenced-by-count":0,"title":["Docetaxel Rechallenge After Chemohormonal Therapy in High-Volume Metastatic Castration-Sensitive Prostate Cancer"],"prefix":"10.7759","author":[{"given":"Kenichi","family":"Hata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Takiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taisuke","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis G","year":"2013","unstructured":"Gravis G, Fizazi K, Joly F, et al.. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013, 14:149-58. 10.1016\/S1470-2045(12)70560-0","journal-title":"Lancet Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney CJ","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, et al.. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015, 373:737-46. 10.1056\/NEJMoa1503747","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James ND","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, et al.. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016, 387:1163-77. 10.1016\/S0140-6736(15)01037-5","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE- 1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi K","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, et al.. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE- 1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet. 2022, 399:1695-707. 10.1016\/S0140-6736(22)00367-1","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith MR","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, et al.. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022, 386:1132-42. 10.1056\/NEJMoa2119115","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.09.022","article-title":"Anticancer activity and tolerance of treatments received beyond progression in men treated upfront with androgen deprivation therapy with or without docetaxel for metastatic castration-na\u00efve prostate cancer in the GETUG-AFU 15 Phase 3 trial","volume":"73","author":"Lavaud P","year":"2018","unstructured":"Lavaud P, Gravis G, Foulon S, et al.. Anticancer activity and tolerance of treatments received beyond progression in men treated upfront with androgen deprivation therapy with or without docetaxel for metastatic castration-na\u00efve prostate cancer in the GETUG-AFU 15 Phase 3 trial. Eur Urol. 2018, 73:696-703. 10.1016\/j.eururo.2017.09.022","journal-title":"Eur Urol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2022.09.010","article-title":"UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castration-sensitive prostate cancer","volume":"40","author":"Mahler M","year":"2022","unstructured":"Mahler M, Al-Ezzi E, Shrem NS, et al.. UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castration-sensitive prostate cancer. Urol Oncol. 2022, 40:539.e17-22. 10.1016\/j.urolonc.2022.09.010","journal-title":"Urol Oncol"},{"key":"ref8","unstructured":"US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 5. (2025). Accessed: August 27, 2025: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-8x11.pdf."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock IF","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, et al.. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004, 351:1502-12. 10.1056\/NEJMoa040720","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.04.010","article-title":"The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer","volume":"46","author":"Loriot Y","year":"2010","unstructured":"Loriot Y, Massard C, Gross-Goupil M, et al.. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer. 2010, 46:1770-2. 10.1016\/j.ejca.2010.04.010","journal-title":"Eur J Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2011.11.043","article-title":"Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors","volume":"79","author":"Caffo O","year":"2012","unstructured":"Caffo O, Pappagallo G, Brugnara S, et al.. Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors. Urology. 2012, 79:644-9. 10.1016\/j.urology.2011.11.043","journal-title":"Urology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11364.x","article-title":"Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer","volume":"110","author":"Heck MM","year":"2012","unstructured":"Heck MM, Thalgott M, Retz M, et al.. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer. BJU Int. 2012, 110:E635-40. 10.1111\/j.1464-410X.2012.11364.x","journal-title":"BJU Int"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09296.x","article-title":"Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study","volume":"106","author":"Eymard JC","year":"2010","unstructured":"Eymard JC, Oudard S, Gravis G, et al.. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int. 2010, 106:974-8. 10.1111\/j.1464-410X.2010.09296.x","journal-title":"BJU Int"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09498.x","article-title":"Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer","volume":"107","author":"Di Lorenzo G","year":"2011","unstructured":"Di Lorenzo G, Buonerba C, Faiella A, et al.. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int. 2011, 107:234-9. 10.1111\/j.1464-410X.2010.09498.x","journal-title":"BJU Int"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.10.014","article-title":"Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: results of an Italian multicentre study","volume":"68","author":"Caffo O","year":"2015","unstructured":"Caffo O, De Giorgi U, Fratino L, et al.. Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: results of an Italian multicentre study. Eur Urol. 2015, 68:147-53. 10.1016\/j.eururo.2014.10.014","journal-title":"Eur Urol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.12653","article-title":"Docetaxel rechallenge improves survival in patients with metastatic castration-resistant prostate cancer: a retrospective study","volume":"35","author":"Hung SC","year":"2021","unstructured":"Hung SC, Chang LW, Li JR, et al.. Docetaxel rechallenge improves survival in patients with metastatic castration-resistant prostate cancer: a retrospective study. In Vivo. 2021, 35:3509-19. 10.21873\/invivo.12653","journal-title":"In Vivo"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13447","article-title":"Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease","volume":"17","author":"Schmidt A","year":"2021","unstructured":"Schmidt A, Anton A, Shapiro J, et al.. Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease. Asia Pac J Clin Oncol. 2021, 17:36-42. 10.1111\/ajco.13447","journal-title":"Asia Pac J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2020.06.018","article-title":"Treatment of metastasized prostate cancer beyond progression after upfront docetaxel-A real-world data assessment","volume":"7","author":"Tsaur I","year":"2021","unstructured":"Tsaur I, Heidegger I, van den Bergh RC, et al.. Treatment of metastasized prostate cancer beyond progression after upfront docetaxel-A real-world data assessment. Eur Urol Focus. 2021, 7:1308-15. 10.1016\/j.euf.2020.06.018","journal-title":"Eur Urol Focus"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.02.018","article-title":"Management of patients with advanced prostate cancer-metastatic and\/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022","volume":"185","author":"Gillessen S","year":"2023","unstructured":"Gillessen S, Bossi A, Davis ID, et al.. Management of patients with advanced prostate cancer-metastatic and\/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer. 2023, 185:178-215. 10.1016\/j.ejca.2023.02.018","journal-title":"Eur J Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114392","article-title":"Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies","volume":"160","author":"Hashemi M","year":"2023","unstructured":"Hashemi M, Zandieh MA, Talebi Y, et al.. Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies. Biomed Pharmacother. 2023, 160:114392. 10.1016\/j.biopha.2023.114392","journal-title":"Biomed Pharmacother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/385425-docetaxel-rechallenge-after-chemohormonal-therapy-in-high-volume-metastatic-castration-sensitive-prostate-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T23:41:33Z","timestamp":1756338093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/385425-docetaxel-rechallenge-after-chemohormonal-therapy-in-high-volume-metastatic-castration-sensitive-prostate-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.91143","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,27]]}}}